Fields EJ, Samarel AM, Lewis W. Detection of differentially methylated gene promoters in failing and nonfailing human left ventricle myocardium using computation analysis. Physiol Genomics 45: 597-605, 2013. First published May 21, 2013 doi:10.1152/physiolgenomics.00013.2013.-Human dilated cardiomyopathy (DCM) is characterized by congestive heart failure and altered myocardial gene expression. Epigenetic changes, including DNA methylation, are implicated in the development of DCM but have not been studied extensively. Clinical human DCM and nonfailing control left ventricle samples were individually analyzed for DNA methylation and expressional changes. Expression microarrays were used to identify 393 overexpressed and 349 underexpressed genes in DCM (GEO accession number: GSE43435). Gene promoter microarrays were utilized for DNA methylation analysis, and the resulting data were analyzed by two different computational methods. In the first method, we utilized subtractive analysis of DNA methylation peak data to identify 158 gene promoters exhibiting DNA methylation changes that correlated with expression changes. In the second method, a two-stage approach combined a particle swarm optimization feature selection algorithm and a discriminant analysis via mixed integer programming classifier to identify differentially methylated gene promoters. This analysis identified 51 hypermethylated promoters and six hypomethylated promoters in DCM with 100% cross-validation accuracy in the group assignment. Generation of a composite list of genes identified by subtractive analysis and two-stage computation analysis revealed four genes that exhibited differential DNA methylation by both methods in addition to altered gene expression. Computationally identified genes (AURKB, BTNL9, CLDN5, and TK1) define a central set of differentially methylated gene promoters that are important in classifying DCM. These genes have no previously reported role in DCM. This study documents that rigorous computational analysis applied to microarray analysis of healthy and diseased human heart samples helps to define clinically relevant DNA methylation and expressional changes in DCM. DNA methylation; heart; heart failure; computational analysis; DAMIP CARDIOMYOPATHY (CM) IS A PRIMARY weakness of the myocardium, impaired myocardial perfusion, or an infiltrative process that leads to defective cardiac function and congestive heart failure (4, 15).
DNA methylation; heart; heart failure; computational analysis; DAMIP CARDIOMYOPATHY (CM) IS A PRIMARY weakness of the myocardium, impaired myocardial perfusion, or an infiltrative process that leads to defective cardiac function and congestive heart failure (4, 15) . On a functional basis, CM is classified as ischemic (I)CM (poor tissue perfusion) and nonischemic (D)CM (toxic, metabolic, infectious, or idiopathic etiologies) (26) .
Cardiac myocytes undergo changes in gene transcription during development of DCM, with a characteristic reversion of cardiac gene expression to a "fetal state" (9, 32) . Such changes in gene transcription are regulated by epigenetic modifications that include DNA methylation, histone modification, and others (3, 13, 23) . DNA methylation represents an important epigenetic modification because hypermethylation of gene promoters is associated with repression of gene transcription (41) . Previous studies have used standard statistical methods to identify changes in DNA methylation of the failing myocardium (27, 28) . Advanced computational methods exist that enable us to identify differentially methylated gene promoters that work in concert to promote CM.
Computational analysis is available to identify groups of attributes that change between defined phenotypic states (8, 25, 30, 33) . Using an approach that capitalizes on particle swarm optimization (PSO) modeling and discriminant analysis via mixed integer programming (DAMIP), we can identify DNA methylation peaks that can classify DCM from nonfailing (NF) controls. Previous work using the DAMIP algorithm identified novel changes in biological systems (8, 25, 30, 33) . Combined with gene expression analysis, computational approaches can be validated with physiological changes to identify biologically important changes in DNA methylation.
In the present study, we combined DNA methylation analysis using methylated DNA immunoprecipitation (MeDIP), DNA methylation and gene expression microarray analysis, and robust computational modeling to identify gene promoters that exhibit differentially methylated DNA in human cardiac health and disease. We identified genes known to be associated with cardiovascular diseases and novel genes whose promoter DNA methylation and gene expression changes are good predictors of CM in human myocardial samples. These results incorporate gene expression array results to determine the physiological importance of the identified DNA methylation changes on the failing heart transcriptome. To our knowledge, this is the first systems biological analysis of DNA methylation changes that occur in human heart failure that have been analyzed by this robust approach.
MATERIALS AND METHODS
Human heart samples. Adult human heart samples from DCM left ventricles (LVs, n ϭ 10) were obtained fresh from surgically removed native hearts at Emory University in accordance with Institution Review Board (IRB) protocols. Samples from 10 adult human NF controls were obtained from Loyola University Health System's (LUHS) Cardiovascular Institute Tissue Repository, and from the Gift of Hope Organ and Tissue Donor Network (GOH). The investigation conformed to the principles outlined in the Declaration of Helsinki. A detailed protocol and informed consent document were reviewed by LUHS IRB. Following informed consent from organ donor family members in the case of NF donors and from patients undergoing heart transplantation in the case of DCM donors, tissue samples were surgically removed, quickly frozen in liquid N 2, and stored at Ϫ80°C. The GOH policy is to release tissue for research purposes only after all available transplant teams have been polled, and no suitable organ recipient is found. The reasons for rejecting these hearts for transplant varied but included the presence of other underlying diseases, age, and "risky behavior" prior to death, etc. Once obtained, the tissue is added to the LUHS or Emory Tissue Repository for NF or DCM samples, respectively. All patient identifiers are removed to strictly maintain donor confidentiality and anonymity. Both sample sets included male and female patients.
Gene expression analysis. RNA was extracted from 10 NF and 10 DCM human tissues with the Qiagen Fibrous Tissue RNeasy kit (Qiagen, Valencia, CA). Up to 10 g of total RNA were used to synthesize double-stranded cDNA with the SuperScript DoubleStranded cDNA Synthesis Kit (Invitrogen/Life Technologies, Grand Island, NY). cDNA was labeled with Cy3 and hybridized to a 12 ϫ 135 kb human expression array (Roche) overnight at 42°C. Expression arrays were washed and scanned with a Roche Nimblegen MS200 scanner. Images were analyzed by Nimblescan software as directed by the manufacturer, including RMA normalization and generation of expression data. All NF and DCM samples were averaged together in their respective sets, and outliers were determined by a Grubbs test. Means were generated for each cDNA analyzed, and a P value was determined between the NF and DCM samples for each cDNA by a Student's t-test. Significance was determined as those cDNAs exhibiting a DCM/NF ratio Ͻ 0.5 and Ͼ 2 and a P Ͻ 0.05.
MeDIP. DNA was extracted as previously described with a MagNAPure DNA Extraction System (Roche, Indianapolis, IN) (10) . Total cellular DNA from 10 NF and 10 DCM samples was quantitated and sonicated to obtain an average fragment size of 200 -500 bp. A sample of DNA was set aside for later normalization (denoted "input"), and then a portion of the sonicated DNA was enriched with the MethylCollector Ultra kit (Active Motif, Carlsbad, CA) following the manufacturer's directions. Enriched DNA was subsequently cleaned and denoted as "methylated." Both the methylated and input DNA were amplified using whole genome amplification (Sigma-Aldrich, St. Louis, MO). The amplified DNA was cleaned and quantitated. Samples of the methylated and input DNA were verified for enrichment of methylated DNA using the provided PCR primers (Xist and GAPDH) in the MethylCollector Ultra Kit.
For DNA methylation analysis, Roche Nimblegen 2.1M Deluxe Promoter Arrays were utilized (Roche Nimblegen, Indianapolis, IN). Following the manufacturer's instructions, the DNA was labeled with Cy3 and Cy5 dyes to distinguish methylated and input DNA. Arrays were allowed to hybridize overnight at 42°C. Arrays were washed and were scanned with a Roche Nimblegen MS200 scanner. Images were analyzed with Nimblescan software as directed by the manufacturer [which included normalizing to the input DNA and peak identification using a modified ACME algorithm (38) ], resulting in a final analysis including a P score of the detected methylated DNA peak and annotation of the probe location (GEO accession number: GSE43435).
Subtractive analysis of DNA methylation peaks. Each detected peak was combined into a comprehensive list of DNA methylation peaks for NF and DCM samples. This resulted in 260,480 unique peaks detected in NF samples and 298,450 unique peaks detected in DCM samples. Important peaks were operationally identified as those peaks appearing in at least eight out of 10 of the NF or DCM sample sets. This resulted in 10,286 peaks in NF and 38,676 peaks in DCM that appeared in eight out of 10 samples. These results were then crossanalyzed with the gene expression results to only include those DNA methylation peaks that occurred in the gene promoters of differentially expressed genes. This resulted in a total of 1,059 DNA methylation peaks in 158 gene promoters.
Two-stage computational analysis of DNA methylation peaks. The processed data files from DNA methylation microarrays with the ratio of the methylated DNA sample to the input (total DNA) sample for each DNA set relative to the peaks within promoter regions were used for analysis. A total of 19,156 unique genes were represented by at least one peak in any of the samples, and these genes were used to generate an m*n matrix, where m ϭ 19,156 genes and n ϭ 20 samples, 10 from each group. A score of 0 was assigned if a gene was not found enriched in a sample. An average relative score was used for genes represented by more than one peak.
The data were transformed by using a log10(x ϩ 1) transformation, where x is the matrix representing number of peaks uniquely mapping to a gene promoter. A two-stage gene selection process was used next to identify differentially methylated genes. The Bioconductor software for R was used for statistical analyses. In stage 1, differentially expressed genes were identified by a two-sample Welch test, twosample Wilcoxon test, and limma at false discovery rate (FDR) adjusted significance level of 0.05. Operationally, a gene was classified as being differentially expressed if it was selected by any one of the three methods. This approach enabled us to identify 131 differentially methylated gene promoters. In stage 2, a binary PSO algorithm combined with DAMIP was used to identify genes that displayed changes in promoter methylation (11, 12, 19, 33) . We reported the results with 100% 10-fold cross-validation accuracy for both DCM and NF groups. Stage 2 analysis identified 57 differentially methylated gene promoters.
Functional annotation. The gene ontology (GO) and KEGG pathway enrichment analysis tool in DAVID (11, 12) were used to identify the pathways regulated by the differentially methylated and differentially expressed genes. The DisGeNet Cytoscape plug-in was used to identify known relationships of genes with cardiovascular diseases (2, 40) .
Histone H3 immunodetection. Approximately 50 mg of heart tissue was placed in 1 ml RIPA buffer (Sigma Aldrich) with protease inhibitor cocktail (Sigma Aldrich). The samples were lysed for 2 min at 30 Hz with a TissueLyser (Qiagen) following manufacturer protocols. Lysates were centrifuged at 1,000 g for 5 min, and the supernatant was transferred to new tubes and saved as the tissue lysate. Lysates were analyzed using SDS-PAGE precast Bio-Rad AnyKD gels (Bio-Rad, Hercules, CA). Proteins were transferred to PVDF membranes and processed according to standard procedures. Protein detection utilized chemiluminescent substrate and film. Histone H3 band intensity for each modification was normalized to total histone H3 band intensity. All histone H3 antibodies were obtained from Cell Signaling Technologies (Danvers, MA). At least three NF and three DCM samples were utilized for immunoblot analysis.
Other statistical methods. Statistical methods were performed using Graphpad Prism software (Graphpad, La Jolla, CA). A P Ͻ 0.05 was determined to be significant in all cases unless otherwise noted. A Student's t-test was used when comparing NF to DCM, and a Grubbs test was used to determine outliers. The sample size is identified for each experimental set.
RESULTS
Human heart samples. LV samples from adult human hearts with DCM (n ϭ 10) were obtained fresh from surgically removed native hearts at the time of heart transplantation. Samples from 10 adult human NF controls came from donor specimens deemed unsuitable for clinical use. Demographic data are shown in Table 1 . Of the 20 samples analyzed, the mean age of NF heart donors was 53.0 Ϯ 4.3 yr; mean age of DCM heart donors was 46.1 Ϯ 2.6 yr (P ϭ not significant). Both sample sets included males and females. LV tissue cubes were obtained from each heart, with all samples being treated identically upon collection.
Gene expression changes. RNA was extracted from the 20 human heart samples, and the samples were individually hybridized to gene expression microarrays that analyzed expressional changes in 45,034 transcripts. Following RMA normalization, NF and DCM Log 2 results exhibited a linear relationship between NF and DCM data (Fig. 1A) . We operationally defined significant changes in gene expression as those with: 1) a DCM-to-NF ratio Ͻ 0.5 or Ͼ 2, and 2) a t-test P value Ͻ 0.05. Analysis revealed 742 gene transcripts that were differentially expressed in DCM (Fig. 1B ). Of these, 393 were found to be overexpressed and 349 were found to be underexpressed in DCM (Supplementary Table S1 ). 1 We utilized these 742 differentially expressed genes to determine which DNA methylation changes are associated with modulation of gene expression.
DNA methylation. DNA extracted from the 20 samples was individually enriched for DNA methylation with MeDIP. Each sample was run on a 2.1 M probe deluxe promoter array, with probe coverage 5 kb upstream and 1 kb downstream of the gene start site. Each promoter sequence was analyzed for peaks in DNA methylation using a KS sliding window test based on a modified ACME algorithm (38) . Peaks with a log -10 peak value of Ն 2 were selected as significant and were utilized for further analysis. We first determined if changes in DNA methylation profoundly changed the promoter methylation landscape in DCM. We plotted each detected peak in DCM and NF relative to the transcriptional start site (Fig. 2) . We found that the distribution of DCM and NF peaks followed a similar trend, though there was an overall increase in the number of detectable DNA methylation peaks in DCM that suggests gene promoter hypermethylation is occurring in DCM (Fig. 2) . The modulated DNA methylated regions did not appear to localize to one chromosomal region, suggesting nonspecific chromo- somal targeting of DNA methylation. Using these results, we utilized two separate analytical methods to determine biologically important DNA methylation changes. Subtractive analysis. In the first approach, we used subtractive analysis to determine which DNA methylation peaks were present exclusively in the NF or DCM samples. Since these peaks were annotated at the probe level, comparisons could be made between NF and DCM samples. For the 20 patients analyzed, we identified 260,480 unique peaks in NF and 298,450 unique peaks in DCM (Fig. 3A) . When these two sets were cross-analyzed, only 73,692 peaks were found exclusively in NF samples and 111,662 were exclusive to DCM. To ensure that the peaks detected were reproducible, we selected only those peaks that appeared in eight of the 10 samples. This minimizes array, dye, or sample-associated errors. Using this operational cutoff, we identified 10,286 peaks in NF samples and 38,676 peaks in DCM samples (Fig. 3B ). Of these, 654 were exclusive to NF and 29,044 were exclusive to DCM.
We compared the identified DNA methylation peaks with the differentially expressed genes. This resulted in four functional groups: samples with 1) increased DNA methylation and increased expression in DCM, 2) increased DNA methylation and decreased expression in DCM, 3) decreased DNA methylation and increased expression in DCM, and 4) decreased DNA methylation and decreased expression in DCM. When only the DNA methylation peaks that appeared in eight of 10 samples were selected, we identified 1,059 DNA methylation peaks that associated with changes in DNA methylation (Table 2) . These peaks were limited to only 158 gene promoters (Supplementary Table S2 ). Some of these genes, such as NPPA and SERCA3 (ATP2A3), have known associations with heart failure while others do not (5, 6, 22) . This subtractive analysis capitalizes on individual probe analysis but does not take into account DNA methylation across the entire gene promoter. Further computational approaches were utilized to validate the subtractive analysis algorithm utilized.
Computational analysis. A total of 19,156 unique genes were identified in the NF and DCM DNA methylation samples as a common reference. Not all peaks were present in all samples. Only those promoters appearing in at least 50% of the NF or DCM sample sets were included. This reduced the common reference set to 12,982 unique gene promoters, and further analysis was performed to identify reproducible peaks that were differentially methylated between the two sample sets.
A two-stage analysis was utilized to determine the gene promoters that displayed differential methylation between NF and DCM samples. Before analysis, a gene promoter's methylation characteristics were separated based on two analytical attributes and were treated individually for analysis: 1) frequency of DNA methylation peaks across the promoter, and 2) maximum peak values for each promoter. Each attribute represents an individual characteristic of the DNA methylation status across the promoter and was treated as such. In stage 1, differentially methylated gene promoters were identified from three biostatistical tests to determine the significance in the difference between the two-sample sets, and a gene was identified as being differentially methylated if it was selected by at least one method.
Using this approach, we identified 121 hypermethylated gene promoters in the DCM samples and 10 gene promoters hypermethylated in NF (Supplemental Table S3 ). These analyses suggest an overall increase in gene promoter DNA methylation in the failing human heart, with 12 times as many promoters hypermethylated in DCM. This is consistent with the subtractive analysis results.
In stage 2, we took the results from stage 1 and further distilled the DNA methylation data with advanced analysis. A binary PSO algorithm was used to identify genes that allowed accurate classification of the samples based on leave-one-out cross-validation criteria using a support vector machine classifier, DAMIP (33) . Using this approach, we identified 51 hypermethylated genes in DCM and 6 hypermethylated genes in NF, for a total of 57 differentially methylated gene promoters with a 100% 10-fold cross-validation accuracy for both DCM and NF groups (Supplementary Table S3 ). These 57 differentially methylated gene promoters were identified inde- 3 . Subtractive analysis of DNA methylation peaks. DNA methylation peaks were calculated by a modified ACME algorithm, and peaks were identified as being only found in NF, only found in DCM, or found in both sets. A: 260,480 unique peaks were detected in NF samples, while 298,450 unique peaks were detected in DCM samples. Of those peaks, 186,788 peaks were shared. B: when only those peaks found in 8 out of 10 NF or DCM samples sets were considered, 10,286 peaks were detected in NF and 38,676 peaks were detected in DCM. Of those peaks, 9,632 were shared. (Fig. 4A) . Analysis of log normalized methylation levels of the differentially methylated gene promoters demonstrated similar levels of DNA methylation in the DCM (Fig. 4B) and NF (Fig. 4C ) hypermethylated promoter sets. DNA methylation peaks identified by both methods. We compared the gene lists generated by subtractive analysis and computational analysis to determine which gene promoters were identified by both methods. As the subtractive analysis identified gene promoters that also displayed differential gene expression, the gene promoters that appeared in both lists would have been selected by both DNA methylation methods and differentially expressed. Cross-analysis of the 158 promoters identified by subtractive analysis and the 57 promoters identified by two-stage computational analysis resulted in four gene promoters that appeared in both analyses (Table 3) . Cross-analysis identified TK1, CLDN5, AURKB, and BTNL9 as exhibiting DNA methylation changes by both methods. All four genes displayed hypermethylation in the gene promoter and decreased gene expression in DCM.
Other epigenetic changes. DNA methylation is one of many epigenetic changes that can occur within a cell. Histone modifications also have been found to be important in determining gene expression changes in disease, including DCM (1, 3, 18, 31) . We performed immunoblotting and film densitometry with ChIP-validated antibodies to determine if certain histone modifications increase or decrease during DCM (Fig 5) . We utilized 10 histone H3 antibodies on protein extracts from NF and DCM explants. Densitometry was normalized to total histone H3. We identified statistical changes in four of the screened modifications. For dimethylation modifications of histone H3, dimethyl-K4 decreased by 58%, while dimethyl-K79 increased by nearly 350%. For acetyl modifications of histone H3, acetyl-K14 decreased by 66%, while acetyl-K27 increased by 280%. These results suggest that additional changes in the epigenome are present and may alter gene expression either independently or in combination with DNA methylation changes in DCM.
DISCUSSION
DCM is a complex entity with many factors contributing to the loss of cardiac function. Using clinical samples, we have combined molecular methods for quantitation of DNA methylation with a computationally rigorous analysis to identify interactions between DNA methylation promoters that may be overlooked in standard statistical practices. The results verify DNA methylation changes in gene promoters previously associated with cardiovascular disease while identifying novel genes associated with DCM. It is known that methylation in the promoter regions of genes is critical to modulate gene expression (7) . Studies performed here analyzed gene promoter regions to determine the DNA methylation changes in the failing human heart compared with NF hearts treated in the same way clinically.
We utilized two separate analytical techniques to determine important changes in DNA methylation. In the subtractive approach, only those peaks that were reliably identified (at least eight out of 10 NF or DCM samples) were considered differentially methylated between NF and DCM samples. We A: a cluster dendrogram demonstrated successful grouping of NF and DCM samples based on the 57 differentially methylated gene promoters identified at stage 2 using the binary particle swarm optimization (PSO) feature selection algorithm that evaluated sets of features following to 10,000 iterations and 100% 10-fold cross-validation using the discriminant analysis via mixed integer programming (DAMIP) support vector machine classifier. Distribution of differentially methylated gene promoters in DCM (B) and NF (C) shows similar grouping and peak intensities. also utilized the differential expression results in this analysis to identify only those gene promoters exhibiting differential DNA methylation and a physiological change in gene expression. This enabled a straight-forward analysis that identified probe-level DNA methylation changes. We successfully identified 158 genes that displayed DNA methylation changes in the promoter region and altered gene expression. Of these, Ͼ90% of these genes exhibited hypermethylation in DCM (Table 2 ). This finding suggests that hypermethylation is the predominant DNA methylation change occurring in DCM. This might be attributable to the neurohormonal milieu and/or mechanical overload that accompany the heart failure state. Indeed, widespread hypermethylation of multiple gene promoters could account for the progressive deterioration of cardiac function noted in heart failure of diverse etiologies, wherein a similar progressive deterioration in cardiac performance occurs regardless of a specific, causative etiology. It would be interesting to determine whether treatment modalities known to retard heart failure progression regardless of etiology (for example, beta blockade, ACE inhibition, etc.) also reduce the generalized increase in gene promoter hypermethylation. In the computational approach, a two-step algorithm was utilized to identify gene promoter regions where DNA methylation patterns were altered in DCM hearts. First, we selected only the gene promoters that were present in at least 50% of either the NF or DCM sample set. We used three established statistical methods to determine q values. In the first stage, differentially methylated gene promoters were identified with FDR used as a criterion. This consensus analysis provided 131 gene promoters that displayed differential methylation. Second, these 131 gene promoters from stage 1 underwent a computationally rigorous PSO algorithm and DAMIP classifier. The second stage "predicts" important differentially methylated gene promoters by training the support vector machine (DAMIP) to accurately classify NF and DCM (11, 12, 18, 31) . For these experiments, seven NF and seven DCM samples were used to "train" a computer to identify nonfailing and failing hearts. Using the final three NF and three DCM samples as "unclassified input," we can determine whether a candidate gene promoter can be used to blindly predict if a sample is NF or DCM. By using the original 131 gene promoters as input to use for classification, we could use 57 of these genes to accurately classify a human heart sample as NF or DCM. These 57 provided 100% classification in 10-fold cross-validation, which simply means they could be used to predict NF or DCM samples 100% of the time. While the first method is important in defining statistically significant changes in DNA methylation, the second step enables us to utilize computer learning to blindly predict and classify samples as NF or DCM based solely on DNA methylation changes. Note that stage 2 thus selects those gene groups among the 131 that can classify DCM and NF with 100% accuracy. This eliminates the genes in which the accuracy is Ͻ100%, thus improving the FDR. Again, almost 90% of these promoters were hypermethylated in DCM, reinforcing our previous result. These 57 gene promoters included genes associated with, or in families of genes associated with, cardiovascular disease (e.g., Myl10, RAC1, and STK11/LKB1) (14, 36, 37) . It also identified gene promoters that have no reported association with human DCM.
The cross-analysis of the subtractive and computational results revealed four gene promoters that were identified in both methods. TK1 (thymidine kinase 1) is the cytosolic regulator of thymidine phosphorylation, which is important in cell cycle progression but has low expression in the human heart (29) . However, changes in DNA methylation meant to reduce thymidine phosphorylation in the cytosol by TK1 may be related to thymidine phosphorylation in the mitochondria by TK2. Mutations in TK2 have been shown to cause myopathy in humans (35) , and mutated TK2 in the heart leads to cardiomyopathy in mice (10, 17) . CLDN5 (claudin-5) is a regulator of tight junctions with endothelial cells, and a recent report identified reduced claudin-5 in end-stage human cardiomyopathy (24) . Additionally, patients with diminished claudin-5 develop velocardiofacial syndrome, with 75% of patients exhibiting cardiac defects (34, 39) . AURKB is a cell cycle-related gene encoding a serine-threonine protein kinase with no known role in DCM or cardiac function (21) . However, as AURKB protein can phosphorylate p53 and alter its transcriptional activity, AURKB may be hypermethylated and underexpressed in DCM to alter the expression of other important cardiac genes via intermediate phosphorylation targets (42) . There are no current known associations for BTNL9 with DCM or cardiac function, and our results suggest a novel correlation between BTNL9 promoter methylation and gene expression with DCM. While DNA methylation peaks identified by both methods revealed TK1, CLDN5, AURKB, and BTNL9 gene promoters as exhibiting hypermethylation, it is conceivable that hypermethylation of additional gene promoters may ultimately prove causative in heart failure progression. However, it remains to be proven whether DNA methylation changes per se are functionally relevant to the myriad of gene expression changes found in end-stage heart failure, or whether any of these expression changes are responsible for heart failure progression despite medical or surgical therapy.
To address the data in more detail, we document the changes found in TK1 expression in our accompanying article (16) . Identification of genes with differentially methylated promoters and altered gene expression identifies targets for further molecular analyses. By identifying TK1, CLDN5, AURKB, and BTNL9 with the analyses performed herein, we have only identified genes warranting further study but have not shown how DNA methylation changes may be tied to physiological changes in DCM. In our associated study, we performed molecular analyses on one of these four, TK1, to determine how its DNA methylation and gene expression relate to DCM (16) . In this study, we performed expression, immunoblots, and enzymatic activity assays on TK1. Our results suggest that alterations in TK1 expression stem from reduced TK2 activity. TK2 is the mitochondrial thymidine kinase, and mutations in TK2 have been shown to cause myopathy in humans and cardiomyopathy in mice (10, 17, 35) . The cause of the TK2 deficiency remains to be determined, but these results suggest that TK2 deficiency may lead to the altered TK1 promoter methylation and gene expression. That work serves as an example of additional studies required to validate the other three genes identified by computational analysis. Finally, other epigenetic changes can lead to altered gene expression. In fact, gene expression analysis combined with only the subtractive DNA methylation analysis identified 75 genes with hypermethylated DNA in the gene promoter but increased gene expression. Hypermethylated DNA is important in silencing genes, and our results suggest that additional epigenetic mechanisms may contribute to the gene expression changes. We are not currently aware of any study that provides a hierarchy of epigenetic modification effects on gene expression (i.e., does hypermethylation override histone modifications if present near each other, do histone modifications override hypermethylation, do they work together, or do they cancel each other), but this is an important area in determining how epigenetic changes may or may not alter gene expression. One approach is to perform ChIP-Chip or ChIP-Seq analysis with a variety of modifications, determine the relationship of the modification sites to gene expression, and finally determine how all analyzed modifications interact with each other. To this end, we screened 10 histone H3 modifications (five acetylation and five dimethylation) as previous reports have demonstrated the importance of histone modifications on gene expression in the heart (1, 3). Our results identified four histone H3 modifications (dimethyl-K4, dimethyl-K79, acetyl-K14, and acetyl-K27) that significantly changed in DCM. While these modifications are the most likely to correlate with expression changes based on the magnitude of change between NF to DCM, other histone modifications (both those analyzed and not analyzed here) may be important as they may directly target genes important for normal cardiac function. For both dimethyl-and acetyl-H3 modifications, there is not a trend for all samples to either increase or decrease, implying that targeted H3 residue modifications are occurring to impact gene expression in DCM. These histone H3 results illustrate that other epigenetic changes are occurring in DCM beside DNA methylation and may explain why some differentially expressed genes do not display DNA methylation changes and why some gene promoters display sites of hypermethylation with an associated increase in gene expression. There are some data to indicate that histone H3 modifications may also act specifically in DCM. For instance, di-and trimethylation of lysine 9 of histone 3 (H3K9) and binding of heterochromatin protein 1 (HP1) to the promoter regions of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were substantially reduced in end-stage human heart failure. Furthermore, an acute increase in cardiac preload induced HDAC4 nuclear export, H3K9 demethylation, HP1 dissociation from the promoter region, and activation of the ANP gene. These processes were reversed in hearts with myocyte-specific deletion of HDAC4. (20) Upregulation of ANP and BNP is a common feature of the heart failure state, and in fact BNP is a valuable biomarker for heart failure detection and a guide for therapy; it is interesting to speculate that this and other H3 modifications may be a useful diagnostic and therapeutic tool in subsets of DCM patients.
In conclusion, this work provides a global analysis of human gene promoter DNA methylation in the LVs of the human DCM heart compared with human NF hearts. Subtractive and computational analyses were effective approaches to identify novel genes whose promoters were differentially methylated, many important in normal cardiac function. Both methods identified four hypermethylated gene promoters with reduced gene expression that may be critical to maintaining normal cardiac function. Further studies will explore how each of these genes is important in the development of DCM and how these genes may work in groups to promote DCM and other cardiovascular diseases.
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